Keele, UK, 1 February 2007: UK-based Cobra Biomanufacturing Plc (AIM: CBF) today announces an agreement with Pharmexa for the manufacture of the protein vaccine PX107 for use in Phase I clinical trials for bone disorders. The program will include cell banking, process development and GMP manufacture.
